FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201743305> ?p ?o ?g. }

• W3201743305 endingPage "32" @default.
• W3201743305 startingPage "19" @default.
• W3201743305 abstract "The World Health Organization endorses molecular subclassification of endometrial endometrioid carcinomas (EECs). Our objectives were to test the sensitivity of tumor morphology in capturing p53 abnormal (p53abn) cases and to model the impact of p53abn on changes to ESGO/ESTRO/ESP (European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology) risk stratification. A total of 292 consecutive endometrial carcinoma resections received at Foothills Medical Centre, Calgary, Canada (2019-2021) were retrieved and assigned to ESGO risk groups with and without p53 status. Three pathologists reviewed the representative H&E-stained slides, predicted the p53 status, and indicated whether p53 immunohistochemistry (IHC) would be ordered. Population-based survival for endometrial carcinomas diagnosed during 2008-2016 in Alberta was obtained from the Alberta Cancer Registry. The cohort consisted mostly of grade 1/2 endometrioid carcinomas (EEC1/2; N = 218, 74.6%). One hundred and fifty-two EEC1/2 (52.1% overall) were stage IA and 147 (50.3%) were low risk by ESGO. The overall prevalence of p53abn and subclonal p53 was 14.5 and 8.3%, respectively. The average sensitivity of predicting p53abn among observers was 83.6%. Observers requested p53 IHC for 39.4% with 98.5% sensitivity to detect p53abn (99.6% negative predictive value). Nuclear features including smudged chromatin, pleomorphism, atypical mitoses, and tumor giant cells accurately predicted p53abn. In 7/292 (2.4%), p53abn upgraded ESGO risk groups (2 to intermediate risk, 5 to high risk). EEC1/2/stage IA patients had an excellent disease-specific 5-year survival of 98.5%. Pathologists can select cases for p53 testing with high sensitivity and low risk of false negativity. Molecular characterization of endometrial carcinomas has great potential to refine ESGO risk classification for a small subset but offers little value for approximately half of endometrial carcinomas, namely, EEC1/2/stage IA cases." @default.
• W3201743305 created "2021-10-11" @default.
• W3201743305 creator A5019905621 @default.
• W3201743305 creator A5026586433 @default.
• W3201743305 creator A5026729348 @default.
• W3201743305 creator A5028408259 @default.
• W3201743305 creator A5044874564 @default.
• W3201743305 creator A5070151942 @default.
• W3201743305 creator A5074182063 @default.
• W3201743305 creator A5077261801 @default.
• W3201743305 creator A5085173346 @default.
• W3201743305 creator A5086449500 @default.
• W3201743305 date "2021-10-01" @default.
• W3201743305 modified "2023-10-17" @default.
• W3201743305 title "Selection of endometrial carcinomas for <scp>p53</scp> immunohistochemistry based on nuclear features" @default.
• W3201743305 cites W1812181366 @default.
• W3201743305 cites W1981507269 @default.
• W3201743305 cites W2013168905 @default.
• W3201743305 cites W2033605022 @default.
• W3201743305 cites W2041440766 @default.
• W3201743305 cites W2081813122 @default.
• W3201743305 cites W2097409147 @default.
• W3201743305 cites W2102075419 @default.
• W3201743305 cites W2417320495 @default.
• W3201743305 cites W2508098025 @default.
• W3201743305 cites W2572313444 @default.
• W3201743305 cites W2790418701 @default.
• W3201743305 cites W2793281906 @default.
• W3201743305 cites W2793707558 @default.
• W3201743305 cites W2793962581 @default.
• W3201743305 cites W2794053055 @default.
• W3201743305 cites W2904313334 @default.
• W3201743305 cites W2907440433 @default.
• W3201743305 cites W2973153606 @default.
• W3201743305 cites W2994917102 @default.
• W3201743305 cites W2995292698 @default.
• W3201743305 cites W2996314623 @default.
• W3201743305 cites W3014600325 @default.
• W3201743305 cites W3045983904 @default.
• W3201743305 cites W3046405914 @default.
• W3201743305 cites W3047152751 @default.
• W3201743305 cites W3091377283 @default.
• W3201743305 cites W3095464641 @default.
• W3201743305 cites W3112053888 @default.
• W3201743305 cites W3114074286 @default.
• W3201743305 cites W3132563712 @default.
• W3201743305 cites W3145769307 @default.
• W3201743305 cites W3158717919 @default.
• W3201743305 cites W3168445295 @default.
• W3201743305 doi "https://doi.org/10.1002/cjp2.243" @default.
• W3201743305 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34596362" @default.
• W3201743305 hasPublicationYear "2021" @default.
• W3201743305 type Work @default.
• W3201743305 sameAs 3201743305 @default.
• W3201743305 citedByCount "12" @default.
• W3201743305 countsByYear W32017433052022 @default.
• W3201743305 countsByYear W32017433052023 @default.
• W3201743305 crossrefType "journal-article" @default.
• W3201743305 hasAuthorship W3201743305A5019905621 @default.
• W3201743305 hasAuthorship W3201743305A5026586433 @default.
• W3201743305 hasAuthorship W3201743305A5026729348 @default.
• W3201743305 hasAuthorship W3201743305A5028408259 @default.
• W3201743305 hasAuthorship W3201743305A5044874564 @default.
• W3201743305 hasAuthorship W3201743305A5070151942 @default.
• W3201743305 hasAuthorship W3201743305A5074182063 @default.
• W3201743305 hasAuthorship W3201743305A5077261801 @default.
• W3201743305 hasAuthorship W3201743305A5085173346 @default.
• W3201743305 hasAuthorship W3201743305A5086449500 @default.
• W3201743305 hasBestOaLocation W32017433051 @default.
• W3201743305 hasConcept C121608353 @default.
• W3201743305 hasConcept C126322002 @default.
• W3201743305 hasConcept C142160229 @default.
• W3201743305 hasConcept C142724271 @default.
• W3201743305 hasConcept C143998085 @default.
• W3201743305 hasConcept C146357865 @default.
• W3201743305 hasConcept C151730666 @default.
• W3201743305 hasConcept C204232928 @default.
• W3201743305 hasConcept C2777088508 @default.
• W3201743305 hasConcept C2777546739 @default.
• W3201743305 hasConcept C2908647359 @default.
• W3201743305 hasConcept C29456083 @default.
• W3201743305 hasConcept C71924100 @default.
• W3201743305 hasConcept C72563966 @default.
• W3201743305 hasConcept C86803240 @default.
• W3201743305 hasConcept C99454951 @default.
• W3201743305 hasConceptScore W3201743305C121608353 @default.
• W3201743305 hasConceptScore W3201743305C126322002 @default.
• W3201743305 hasConceptScore W3201743305C142160229 @default.
• W3201743305 hasConceptScore W3201743305C142724271 @default.
• W3201743305 hasConceptScore W3201743305C143998085 @default.
• W3201743305 hasConceptScore W3201743305C146357865 @default.
• W3201743305 hasConceptScore W3201743305C151730666 @default.
• W3201743305 hasConceptScore W3201743305C204232928 @default.
• W3201743305 hasConceptScore W3201743305C2777088508 @default.
• W3201743305 hasConceptScore W3201743305C2777546739 @default.
• W3201743305 hasConceptScore W3201743305C2908647359 @default.
• W3201743305 hasConceptScore W3201743305C29456083 @default.
• W3201743305 hasConceptScore W3201743305C71924100 @default.

• next